PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
SMi Group

Press Release


Receive press releases from SMi Group: By Email RSS Feeds:

Spotlight on Key Sessions You Cannot Miss at SMi's Ophthalmic Drugs


SMiís Presents Europe's Leading Ophthalmic Conference, Ophthalmic Drugs

London, United Kingdom, September 13, 2017 --(PR.com)-- The ophthalmic market is expected to reach $21 billion by the year 2022. Ocular disease therapy has seen a surge in innovation in areas ranging from glaucoma to macular degeneration and diabetic retinopathy.

Featuring an exceptional line-up of keynote speakers from industry leading organisations, Europe's leading conference on Ophthalmic Drugs arrives at the perfect time to discuss the latest approaches in key areas such as ocular diseases, drug delivery, pre-clinical and clinical trials, computer technologies and therapies for diabetic macular oedema. Agenda highlights will include a spotlight on therapies for glaucoma, diabetes and approaches to drug release and delivery.

Spotlight

- Minimally Invasive Glaucoma Surgery for various glaucoma treatments will address the use of conjugate drugs and a new prostaglandin drug product co-developed by Santen, called 'Omidenepag Isopropyl.' - Naj Sharif, Executive Director in R&D, Head, Global Alliances & External Research, Santen Inc

- Non-Proliferative Diabetic Retinopathy. The therapies and solutions for this disease will be examined, including light and laser therapy and oral therapies as well as the use of steroids. - Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim

- Nanotechnology, and how this can be utilised to develop extended release therapies for glaucoma, cataract, AMD and DME indications. - Tomas Navratil, Senior Vice President, Development, Envisia Therapeutics

- Diabetic Macular Oedema (DMO) is a leading cause of vision loss in the working-age population worldwide. We will discuss the challenges encountered during clinical development and market access for a revolutionary 36 month intra-vitreal steroid implant. There will also be an emphasis on the importance of ‘Real World Data’. - Steve Morris, VP, Medical Director, UK and Head of Medical Affairs EU, Alimera Sciences

Further information is available at: www.ophthalmicdrugs.com/prc

For those looking to attend there is currently a £200 early-bird saving.

SMi Presents the Launch of…
Ophthalmic Drugs
Date: 28th – 29th November 2017
Location: Kensington, London
Website: www.ophthalmicdrugs.com/prc

Sponsored by: Leica Microsystems | Experimentica

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact Information
SMi Group
Pav Solanki
+44 (0) 20 7827 6048
Contact
http://www.ophthalmicdrugs.com/prc7

Click here to view the list of recent Press Releases from SMi Group
Promote Your Business